OneSource Speci. (ONESOURCE)

FairStock Score: 29/100 — RISKY

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Top-line momentum is strong: 5-year revenue CAGR of 133.09% and latest quarterly sales of ₹290 Cr.
• Current debt/equity ratio is low at 0.22, giving limited balance-sheet leverage risk.
• High current sales growth of 29.97% shows the business is still expanding despite losses.
• Book value per share of ₹513.04 provides some tangible base, though P/B is 3.45.

Concerns

• Deep unprofitability: latest quarter net loss of ₹89 Cr and profit growth of -417.62%.
• Negative free cash flow of -₹269 Cr, implying the company is burning cash.
• Extreme valuation: P/E 504.98, EV/EBITDA 93.21, and P/B 3.45 with zero dividend yield.
• Weak fundamentals: ROE 0.34%, ROCE 5.52%, Piotroski F-Score 4/9, Altman Z-Score 2.32, and promoter holding only 29.93%.

AI Analysis

As a value investor, I don't ask whether a company's sales are growing; I ask whether those sales can create durable earnings and cash for owners. OneSource Speci fails that test today. The top line is remarkable: a five-year revenue CAGR of 133.09%, and a 29.97% sales growth with ₹290 crore of revenue in the latest quarter. But this is a high-revenue, loss-making machine. The same quarter produced a net loss of ₹89 crore, and profit growth is -417.62%. Free cash flow is negative ₹269 crore. So the business is consuming capital while the market places a ₹15,437 crore valuation on it. At ₹1,768.40, I am asked to pay a P/E of 504.98, an EV/EBITDA of 93.21, and 3.45 times book value—while getting a return on equity of only 0.34% and a return on capital employed of 5.52%. Graham's margin-of-safety principle is absent. The low debt/equity of 0.22 is the only balance-sheet comfort, but a company that burns cash and loses money can quickly alter that. The Piotroski F-Score of 4/9, Altman Z-Score of 2.32, zero dividend, and promoter holding of just 29.93% all point to a speculative situation, not a compounding franchise. Growth is not a moat. In pharma, high growth without profit invites competition and destroys value. I would leave this stock to the speculators. If management can convert revenue growth into genuine profits and positive cash flows, I will revisit. Until then, this is a turnaround candidate—not an investment.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer